QSAR analysis of [(biphenyloxy)propyl]isoxazoles: agents against coxsackievirus B3.

BACKGROUND Antiviral drugs are urgently needed for the treatment of acute and chronic diseases caused by enteroviruses such as coxsackievirus B3 (CVB3). The main goal of this study is quantitative structure-activity relationship (QSAR) analysis of anti-CVB3 activity (clinical CVB3 isolate 97927 [log IC50, µM]) and investigation of the selectivity of 25 ([biphenyloxy]propyl)isoxazoles, followed by computer-aided design and virtual screening of novel active compounds. DISCUSSION The 2D QSAR obtained models are quite satisfactory (R(2) = 0.84-0.99, Q(2) = 0.76-0.92, R(2)(ext) = 0.62-0.79). Compounds with high antiviral activity and selectivity have to contain 5-trifluoromethyl-[1,2,4]oxadiazole or 2,4-difluorophenyl fragments. Insertion of 2,5-dimethylbenzene, napthyl and especially biphenyl substituents into investigated compounds substantially decreases both their antiviral activity and selectivity. Several compounds were proposed as a result of design and virtual screening. A high level of activity of 2-methoxy-1-phenyl-1H-imidazo[4,5-c]pyridine (sm428) was confirmed experimentally. CONCLUSION Simplex representation of molecular structure allows successful QSAR analysis of anti-CVB3 activity of ([biphenyloxy]propyl)isoxazole derivatives. Two possible ways of battling CVB3 are considered as a future perspective.

[1]  Kimito Funatsu,et al.  GA Strategy for Variable Selection in QSAR Studies: GA-Based PLS Analysis of Calcium Channel Antagonists , 1997, J. Chem. Inf. Comput. Sci..

[2]  Spencer Hudson,et al.  Efficacy and Safety of Oral Pleconaril for Treatment of Colds Due to Picornaviruses in Adults: Results of 2 Double-Blind, Randomized, Placebo-Controlled Trials , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. O'Connell,et al.  Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies. , 1996, Antiviral research.

[4]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[5]  Nina Nikolova-Jeliazkova,et al.  QSAR Applicability Domain Estimation by Projection of the Training Set in Descriptor Space: A Review , 2005, Alternatives to laboratory animals : ATLA.

[6]  Anatoly G. Artemenko,et al.  QSAR Analysis of Anti-Coxsackievirus B3 Nancy Activity of 2-Amino-3-Nitropyrazole[1,5-α]Pyrimidines by Means of Simplex Approach , 2007 .

[7]  E. Muratov,et al.  Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. , 2007, Journal of medicinal chemistry.

[8]  V. Makarov,et al.  New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. , 2009, Antiviral research.

[9]  M G Rossmann,et al.  The structure of coxsackievirus B3 at 3.5 A resolution. , 1995, Structure.

[10]  V. Racaniello.  Picornaviridae : the viruses and their replication , 2001 .

[11]  Eugene N Muratov,et al.  The analysis of structure-anticancer and antiviral activity relationships for macrocyclic pyridinophanes and their analogues on the basis of 4D QSAR models (simplex representation of molecular structure). , 2002, Acta biochimica Polonica.

[12]  F. Hayden,et al.  Relationship of Pleconaril Susceptibility and Clinical Outcomes in Treatment of Common Colds Caused by Rhinoviruses , 2005, Antimicrobial Agents and Chemotherapy.

[13]  S. Schüler,et al.  Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. , 2005, The Journal of antimicrobial chemotherapy.

[14]  C. Hansch,et al.  Understanding human rhinovirus infections in terms of QSAR. , 2007, Virology.

[15]  Hugo Kubinyi,et al.  Evolutionary variable selection in regression and PLS analyses , 1996 .

[16]  Paola Gramatica,et al.  The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .

[17]  Anatoly G. Artemenko,et al.  Hit QSAR Analysis of Anti-Coxsackievirus B3 Activity of [(Biphenyloxy)Propyl]Isoxazole Derivatives , 2008 .

[18]  Victor Kuzmin,et al.  Hierarchical QSAR technology based on the Simplex representation of molecular structure , 2008, J. Comput. Aided Mol. Des..

[19]  P Wutzler,et al.  Identification of individual structural fragments of N,N'-(bis-5-nitropyrimidyl)dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. , 2007, The Journal of antimicrobial chemotherapy.

[20]  Kirk U. Knowlton,et al.  Viral Myocarditis: From the Perspective of the Virus , 2009, Circulation.

[21]  J. Leszczynski,et al.  The effect of nitroaromatics' composition on their toxicity in vivo: novel, efficient non-additive 1D QSAR analysis. , 2008, Chemosphere.

[22]  M. Rossmann,et al.  Structural and Virological Studies of the Stages of Virus Replication That Are Affected by Antirhinovirus Compounds , 2004, Journal of Virology.

[23]  V. Makarov,et al.  Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. , 2005, The Journal of antimicrobial chemotherapy.

[24]  E. Muratov,et al.  QSAR Analysis of Antimicrobial Activity of 4‐thiazolidone Derivatives , 2009 .

[25]  Eugene N Muratov,et al.  Per aspera ad astra: application of Simplex QSAR approach in antiviral research. , 2010, Future medicinal chemistry.

[26]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[27]  Jerzy Leszczynski,et al.  The effects of characteristics of substituents on toxicity of the nitroaromatics: HiT QSAR study , 2008, J. Comput. Aided Mol. Des..

[28]  Jerzy Leszczynski,et al.  Consensus QSAR Modeling of Phosphor‐Containing Chiral AChE Inhibitors , 2009 .

[29]  Paul Geladi,et al.  Interactive variable selection (IVS) for PLS. Part 1: Theory and algorithms , 1994 .

[30]  A. Bruu,et al.  Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses and Newer Enteroviruses , 2003 .

[31]  Victor Kuzmin,et al.  Application of Random Forest Approach to QSAR Prediction of Aquatic Toxicity , 2009, J. Chem. Inf. Model..

[32]  S. Wold,et al.  A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: Theory and algorithm , 1994 .

[33]  D. Wheeler,et al.  A formidable challenge: the diagnosis and treatment of viral myocarditis in children. , 2003, Critical care clinics.

[34]  E. De Clercq,et al.  Selective inhibitors of picornavirus replication , 2008, Medicinal research reviews.

[35]  Anatoly G. Artemenko,et al.  QSAR Analysis of Cytotoxicity in HeLa Cells , 2008 .

[36]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[37]  M. Rossmann,et al.  The structure of coxsackievirus B3. , 1997, Current topics in microbiology and immunology.

[38]  M. Schmidtke,et al.  A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. , 2001, Journal of virological methods.

[39]  E. Muratov,et al.  Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure , 2005, SAR and QSAR in environmental research.

[40]  D. Barnard,et al.  Current status of anti-picornavirus therapies. , 2006, Current pharmaceutical design.

[41]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[42]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[43]  J. Rollinger,et al.  The human rhinovirus: human‐pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery , 2010, Medicinal research reviews.

[44]  M. Rossmann,et al.  Picornavirus-receptor interactions. , 2002, Trends in microbiology.

[45]  M G Rossmann,et al.  Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Daniel C. Pevear,et al.  VP1 Sequencing of All Human Rhinovirus Serotypes:Insights into Genus Phylogeny and Susceptibility to AntiviralCapsid-BindingCompounds , 2004, Journal of Virology.

[47]  F. Hayden,et al.  Oral Pleconaril Treatment of Picornavirus-Associated Viral Respiratory Illness in Adults: Efficacy and Tolerability in Phase II Clinical Trials , 2002, Antiviral therapy.

[48]  Daniel C. Pevear,et al.  Activity of Pleconaril against Enteroviruses , 1999, Antimicrobial Agents and Chemotherapy.